Industrial manufacturing

10 October 2021

D. Parsons (Cambridge (MA) - USA)

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.Retour ligne automatique
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing. These manufacturing advances include scalable and Flexible manufacturing sites, Cell-free manufacturing process, Non-product-dedicated plants, Lower CapEx requirements and Smaller manufacturing footprint than traditional vaccines.

Discussion forum

GERPAC provides for its members a discussion forum specifically devoted to technology in hospital pharmacy

Access forum

Association Loi 1901
Siège social : Chez Jean-Yves Jomier / 8ter rue Léon Bussat, 64000 PAU
Immatriculation formation N° 72 64 035 30 64
Contact us Legal notes - Management of personal data
Réalisation : Développeur web WordPress & SPIP freelance